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M A J O R A R T I C L E
Prognostic Factors in Severe Exacerbation
of Chronic Hepatitis B
Man-Fung Yuen,1 Erwin Sablon,3 Chee-Kin Hui,1 Tak-Ming Li,4 He-Jun Yuan,1 Danny Ka-Ho Wong,1
Joke Doutreloigne,3 Veerle Bogaerts,3 Benjamin Chun-Yu Wong,1 Sheung-Tat Fan,2 and Ching-Lung Lai1
Departments of 1Medicine and 2Surgery, University of Hong Kong, Queen Mary Hospital, Hong Kong, China; 3Innogenetics NV, Ghent, Belgium;
and 4Macau Central Hospital, Macau, China
Forty-seven patients with severe hepatitis B exacerbation were compared with patients who had mild exac-
erbation ( ) or no exacerbation ( ). Seventeen patients (36.2%) died or underwent liver trans-np 96 np 96
plantation. Preexisting cirrhosis and a prothrombin time (PT) of 130 s were associated with adverse outcome
in 60.9% and 87.5% of patients, respectively. The rate of adverse outcome increased to 92.3% when albumin
levels of 35 g/L and bilirubin levels of 1200 mM were present. Other factors associated with adverse outcomes
included peak bilirubin level, peak PT, time to reach peak PT, and the presence of encephalopathy and/or
ascites. There was no difference in the frequency of precore mutations in patients with severe or mild exac-
erbation or without exacerbation. A significantly lower prevalence of core promoter mutants was found in
patients with severe exacerbation (50%), compared with those who had mild exacerbation (81.3%; ).Pp .004
Patients with severe exacerbation of hepatitis B with poor prognostic factors should be considered for early
liver transplantation.
Chronic hepatitis B virus (HBV) infection is a disease
of global importance that affects ∼400 million people
[1]. Exacerbation of chronic HBV infection occurs in
∼40%–50% of hepatitis B e antigen (HBeAg)–positive
patients and in 15%–30% of patients positive for an-
tibodies against HBeAg (anti-HBe) [2–6]. Although
these exacerbations are usually transient and asymp-
tomatic, 1%–2.4% of patients later develop hepatic de-
compensation [3, 7, 8].
Patients with severe exacerbation pose a unique clin-
ical challenge. Generally, they either experience spon-
taneous recovery with receipt of conservative treatment
after prolonged hospitalization, or they die as a result
of irreversible hepatic decompensation. The latter pa-
tients may benefit from early liver transplantation. To
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date, to our knowledge, there are no studies that have
examined the prognostic factors for HBV-infected pa-
tients with severe exacerbation. Such prognostic factors
could be important in determining which patients
might benefit from early liver transplantation.
In addition, the role of precore and core promoter
mutations in causing severe exacerbation is still con-
troversial. Although some studies have suggested that
precore mutations are associated with fatal exacerbation
of chronic hepatitis B [9], the evidence remains incon-
clusive. Therefore, we sought to identify the prognostic
factors for patients with severe exacerbation of chronic
HBV infection and to examine the role of precore and
core promoter mutations in such exacerbations.
PATIENTS AND METHODS
In this study, which was performed from 1 January 1998
through 31 December 2000, a total of 2542 patients
with chronic hepatitis B were examined at the Hepatitis
Clinic, Department of Medicine, University of Hong
Kong, Queen Mary Hospital, Hong Kong, China.
Eighty-nine patients with chronic hepatitis B were ad-
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mitted to the hospital with symptomatic hepatitis. Of these
patients, 47 had acute exacerbation of chronic HBV infection
diagnosed and were recruited into the current study. All 47
patients had a sudden increase in the serum alanine amino-
transferase (ALT) level from normal levels to more than twice
the upper limit of normal. The other 42 patients were excluded
from the study because they had the following concomitant
conditions: 22 had acute hepatitis A or E, 5 were receiving
antituberculosis treatment causing liver derangement, and 15
had alcoholic hepatitis. None of the patients had superimposed
hepatitis C or D documented by the absence of the respective
antibodies tested by Abbott Laboratories (Chicago, IL).
Because of the deranged clotting profiles in patients with
severe exacerbation, liver biopsy was deemed unethical, and,
therefore, liver biopsies were not performed. Cirrhosis was de-
fined by ultrasonographic evidence of a small-sized and irreg-
ular liver, with or without splenomegaly, and/or a serum al-
bumin level of 35 g/L recorded 3 months before the episode
of acute exacerbation. All patients with cirrhosis were graded
by the Child-Pugh score according to parameters obtained 3
months before the onset of acute exacerbation. Liver biochem-
istry values, including serum albumin, bilirubin, ALT, aspartate
aminotransferase, alkaline phosphatase, a-fetoprotein, pro-
thrombin time (PT), arterial ammonia (NH3), urea, creatinine,
and complete blood count, were determined at admission to
the hospital. The liver biochemistry values, PT, and renal func-
tion were monitored daily after admission until the patient’s
condition stabilized. Patients who died or who required liver
transplantation were defined as having an adverse outcome.
The hepatitis B serological markers were determined by EIA
(Abbott Laboratories). Serum HBV DNA levels at admission
were measured using the Digene Hybrid Capture II assay (Di-
gene; lower limit of detection, copies/mL). For pa-60.14 10
tients with HBV DNA levels that were undetectable by the
Digene Hybrid Capture II assay, HBV DNA levels were further
measured using the Cobas Amplicor HBV Monitor Test (Roche
Diagnostics; lower limit of detection, 200 copies/mL) whenever
adequate serum samples were available.
The presence of precore and core promoter mutations was
tested by a research version of the line probe assay (INNO-
LiPA HBV precore), which was developed by Innogenetics NV.
The test contained specific probes covering the following mo-
tifs: (1) core promoter nt 1762/1764 wild type (A/G), (2) core
promoter nt 1762/1764 mutant (A/A), (3) core promoter nt
1762/1764 mutant (A/T), (4) core promoter nt 1762/1764 mu-
tant (T/A), (5) precore codon 28 (nt 1896) wild type (TGG),
and (6) precore codon 28 (nt 1896) stop codon (TAG). The
probes were applied on a nitrocellulose membrane, as described
elsewhere [10]. In brief, HBV DNA was amplified for the core
promoter/precore region by 5′ biotinylated primers [11]. After
reverse hybridization of the biotinylated PCR fragments in the
LiPA format, streptavidin–alkaline phosphatase incubation and
color development were used to identify reactive probes. The
precore and core promoter mutations were tested in 24 patients
(14 HBeAg-positive patients and 10 anti-HBe–positive pa-
tients). Of the other 23 patients, 14 had insufficient serum
samples available and 9 had undetectable HBV PCR products,
thereby precluding LiPA testing. The prevalence of precore and
core promoter mutations in the 24 patients was compared with
the prevalence in 2 control groups of HBV-infected patients
from our Hepatitis Clinic, and control patients were matched
with study patients by HBeAg and anti-HBe status at a ratio
of 4:1. The first control group comprised 96 HBV-infected
patients who had mild exacerbations (defined as an increase in
serum ALT to more than twice the upper limit of normal, with
the patients having no symptoms of hepatitis and no hepatic
complications). The second control group comprised 96 HBV-
infected patients with persistently normal ALT levels.
Presence of YMDD variant HBV was tested in the 2 patients
who were receiving lamivudine before presentation by means
of another line probe assay (INNO-LiPA HBV DR), which was
developed by Innogenetics NV and which has been described
elsewhere [12].
All statistical analyses were performed by SPSS for Windows,
version 10.0 (SPSS). The Mann-Whitney U test was used for
continuous variables with skewed distribution, and the x2 test
with Yates’ correction or Fisher’s exact test was used for cat-
egorical variables. Logistic regression analyses were performed
to test the associations between different variables and adverse
outcome. Statistical significance was defined as .P ! .05
RESULTS
Presenting features. The demographic data and clinical fea-
tures at the time of presentation of the 47 patients are shown
in table 1. Fifteen patients presented to our unit with acute
exacerbation, and 32 developed exacerbation of HBV infection
during follow-up at our Hepatitis Clinic.
HBV DNA and HBV virological markers. Fourteen
(29.8%) of 47 patients had undetectable HBV DNA levels, as
determined by the Digene Hybrid Capture II assay. Of these
14 patients, 10 had sufficient serum samples available for fur-
ther testing with the Cobas Amplicor Monitor Test. Seven such
patients had detectable HBV DNA levels (range, 208–6780 cop-
ies/mL), as determined with the more sensitive assay. Among
the 23 HBeAg-positive patients, 3 (13.0%) had HBeAg sero-
conversion. Among 24 anti-HBe–positive patients, 1 (4.2%)
had seroreversion to HBeAg.
Adverse outcome. Fifteen of the 47 patients died, and 2
patients underwent liver transplantation. The frequency of ad-
verse outcome in patients with severe exacerbation of HBV
infection was 36.2% (17 of 47 patients).
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Table 1. Demographic data for patients with severe exacer-
bation of chronic hepatitis B at admission.
Variable Value
No. of patients 47
Age, median years (range) 39 (18–69)
Ratio of men to women 39:8
Ratio of HBeAg-positive patients
to anti-HBe–positive patients 23:24
Preexisting cirrhosis 23 (48.9)
Child-Pugh grade
A 2
B 12
C 9
ALT level, median U/L (range) 615 (100–3840)
HBV DNA level, median
copies106/mL (range) 0.62 (!0.14–1392)
Symptoms of hepatitis
Total 47 (100)
Jaundice 40 (85.1)
Ascites 13 (27.7)
Encephalopathy 9 (19.1)
Variceal bleeding 5 (10.6)
NOTE. Data are no. (%) of patients, unless otherwise indicated. ALT,
alanine aminotransferase; Anti-HBe, antibodies against hepatitis B e antigen;
HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.
Preexisting cirrhosis and Child-Pugh score. The chance
of adverse outcome was higher for patients with cirrhosis than
for patients without cirrhosis (14 [60.9%] of 23 vs. 3 [12.5%]
of 24, respectively; OR, 12.4; 95% CI, 2.9–53.8; ). OfP ! .0001
the 23 patients with cirrhosis, only 2 had grade A cirrhosis,
according to the Child-Pugh score. They were grouped together
with 24 noncirrhotic patients in the following analysis. There
was an increasing chance of adverse outcome in patients with
a worsening Child-Pugh score (noncirrhosis or grade A, 4
[15.4%] of 26; vs. grade B, 5 [41.7%] of 12; vs. grade C, 8
[88.9%] of 9; ).P ! .0001
Serological and biochemical markers at admission to the
hospital. There were no significant differences in the fre-
quency of adverse outcomes between male and female patients
(15 [38.5%] of 39 and 2 [25%] of 8, respectively). Unfor-
tunately, the number of female patients was too low for mean-
ingful statistical analysis. Patients with adverse outcomes had
a higher median age than did patients who survived with
receipt of conservative treatment (median age, 43 years
[range, 35–68 years] vs. 36.5 years [range, 18–69 years], re-
spectively; ). There were no significant differences inPp .027
the frequency of adverse outcomes between HBeAg-positive
and anti-HBe–positive patients (7 [30.4%] of 23 and 10
[41.7%] of 24, respectively).
The differences in the initial laboratory findings between
patients who survived with receipt of conservative management
and patients with adverse outcome are shown in table 2. Pa-
tients with adverse outcomes had significantly lower median
albumin levels, higher median bilirubin levels, more prolonged
PTs, and lower platelet counts at admission to the hospital.
The frequency of adverse outcomes in patients with a PT of
130 s at admission to the hospital was 85.7% (12 of 14 patients),
whereas, for patients who had a PT of 30 s, the frequency
of adverse outcomes was only 15.2% (5 of 33) ( ). OfP ! .0001
the patients with initial albumin levels of 135 g/L and bilirubin
levels of 200 mM, none had adverse outcomes. By contrast,
the incidence of adverse outcomes was 49% (17 of 35) for
patients with albumin levels of 35 g/L, and it was 63% (17
of 27) for those with bilirubin levels of 1200 mM (Pp .001
and , respectively, compared with patients who hadP ! .0001
no adverse outcomes).
A PT of 130 s was the single most important parameter for
poor prognosis. The sensitivity and specificity for predicting
adverse outcomes with a PT of 130 s at presentation were 0.71
and 0.93, respectively. The positive and negative predictive val-
ues were 0.86 and 0.85, respectively. Inclusion of the 2 other
adverse factors (i.e., albumin level of 35 g/L and bilirubin
level of 1200 mM) increased the frequency of adverse outcomes
to 92.3% (12 of 13 patients). This was significantly higher when
compared with patients who did not have all 3 adverse factors
(5 [14.7%] of 34 patients; ). The sensitivity and spec-P ! .0001
ificity for predicting poor outcome by using a combination of
these 3 adverse factors were 0.71 and 0.97, respectively. The
positive and negative predictive values were 0.92 and 0.85,
respectively.
Subsequent serological and biochemical markers. The
clinical conditions of some patients with relatively good liver
function at admission deteriorated subsequently. Patients with
adverse outcomes had a significantly longer peak PT and took
more time to reach the peak PT, compared with those who
survived with receipt of conservative management (median
peak PT, 51.8 s [range, 34–85.3 s] vs. 18.2 s [range, 10.8–42
s], respectively [ ]; median time to reach peak PT, 6P ! .0001
days [range, 1–33 days] vs. 3 days [range, 1–19 days], respec-
tively [ ]). No mortality occurred among patientsPp .026
whose peak PTs were 33 s, whereas 17 (81.0%) of 21 patients
who had peak PTs of 133 s had adverse outcomes ( ).P ! .0001
Patients with adverse outcomes had significantly higher peak
bilirubin levels and took more time to reach the peak bilirubin
level than did those who survived with receipt of conservative
management (median peak bilirubin level, 710 mM [range,
297–960 mM] vs. 167.5 mM [range, 17–805 mM], respectively
[ ]; median time to reach peak bilirubin level, 9 daysP ! .0001
[range, 2–29 days] vs. 3 days [range, 1–26 days], respectively
[ ]). None of the 22 patients whose highest bilirubinPp .02
level was290 mM died, whereas 8 (47.1%) of 17 patients with
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Table 2. Liver biochemistry values and other baseline parameters for patients with
severe exacerbation of chronic hepatitis B who survived with receipt of conservative
management or who had an adverse outcome.
Laboratory value
Patients who survived
with conservative
management
(n p 30)
Patients with
adverse outcomea
(n p 17) P
Albumin, g/L 34 (18–49) 29 (19–33) !.0001
Bilirubin, mM 112.5 (17–805) 515 (201–820) !.0001
Alanine aminotransferase, U/L 765.5 (78–3840) 564 (63–3045) NS
Ammonia, mM 61 (19–122) 97 (31–149) NS
Prothrombin time, s 16.3 (10.8–37.8) 37.1 (17–58.2) !.0001
HBV DNA, copies 106/mL 0.3 (!0.14–1392) 1.48 (!0.14–70) NS
a-Fetoprotein, ng/mL 68 (1–1908) 58 (3–652) NS
Platelet count, cells 109/L 168 (46–344) 129 (51–214) .018
Urea, mM 3.65 (1–6.4) 5.1 (1.3–20.6) NS
Creatinine, mM 87 (65–136) 96 (30–276) NS
NOTE. Data are median (range). HBV, hepatitis B virus; NS, nonsignificant.
a Death or receipt of liver transplant.
a peak bilirubin level of 1290 mM had adverse outcomes
( ). There were no significant differences in peak ALTP ! .0001
levels and the time to reach the peak ALT levels between patients
who survived with receipt of conservative management and
those who had adverse outcomes.
Development of encephalopathy and ascites. Patients who
presented with encephalopathy at admission to the hospital had
more adverse outcomes than did patients who did not have
encephalopathy at admission (7 [77.8%] of 9 vs. 10 [26.3%]
of 38; ). Of the 38 patients in the latter category, 9Pp .007
subsequently developed encephalopathy. These patients also
had a significantly higher frequency of adverse outcome than
did the remaining 29 patients who never developed encepha-
lopathy (6 [66.7%] of 9 vs. 4 [13.8%] of 29; ).Pp .005
Thirteen patients presented with ascites at admission to the
hospital, and the frequency of adverse outcome was significantly
higher than the frequency among the 34 patients without ascites
at admission (8 [61.5%] of 13 vs. 9 [26.5%] of 34; ).Pp .041
The rate of adverse outcome was also significantly higher in
the 4 patients who developed ascites after admission, compared
with those who never developed ascites (3 [75%] of 4 vs. 6
[20%] of 30; ). Patients who developed spontaneousPp .048
bacterial peritonitis (3 patients) and those with variceal bleeding
(5 patients presented with bleeding, and another 5 developed
variceal bleeding after admission) did not have more adverse
outcomes than did patients without these complications. How-
ever, this might be the result of the small number of patients
affected.
Multivariate analyses of the factors associated with adverse
outcome. By use of logistic regression analysis, the indepen-
dent factors associated with adverse outcome for the parameters
at admission included the following: preexisting cirrhosis
( ), high Child-Pugh score ( ), low albuminPp .001 P ! .0001
level ( ), high bilirubin level ( ), prolonged PTPp .001 P ! .0001
( ), and low platelet count ( ). For the subse-P ! .0001 Pp .015
quent monitoring, these factors were as follows: high peak bil-
irubin level ( ), long peak PT ( ), long durationP ! .0001 P ! .0001
to reach the peak PT ( ), development of encephalop-Pp .021
athy ( ), and presence of ascites ( ). There wasP ! .0001 Pp .003
also a trend for a longer time to reach peak bilirubin level to
be an independent factor associated with adverse outcome
( ).Pp .053
Lamivudine therapy. Two patients received lamivudine for
354 and 343 days before admission to the hospital with severe
exacerbation. Both had YMDD to YVDD mutation and re-
covered with receipt of conservative management. Of the re-
maining 45 patients, 17 initiated lamivudine therapy during
the exacerbation. The patients who received lamivudine had
significantly poorer liver functions at admission than did those
who did not receive lamivudine (respective median albumin
levels, 30 vs. 32.5 g/L [ ]; respective median bilirubinPp .044
levels, 440 vs. 136 mM [ ]; and respective median PTs,Pp .002
29.8 vs. 17.2 s [ ]). Ten (58.8%) of 17 patients whoPp .01
received lamivudine had an adverse outcome, whereas only 7
(25%) of 28 patients who did not receive lamivudine had an
adverse outcome ( ). Poor outcome of the patientsPp .051
treated with lamivudine was not related to any delay in the
initiation of lamivudine therapy. The median time between the
onset of symptoms of exacerbation and the initiation of la-
mivudine therapy was 14 days (range, 0–62 days) for those who
experienced adverse outcomes and 27 days (range, 2–56 days)
for those who did not ( ).Pp .27
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Table 3. Demographic data for and the prevalence of precore mutation and core promoter mutation among patients
with hepatitis B who have different levels of exacerbation.
Characteristic
Level of exacerbation
Severe Mild None
No. of patients 24 96 96
Age, median years (range) 39.5 (25 –69) 39.5 (18–71) 39.8 (18–82)
Ratio of men to women 20:4 76:20 65:31
Ratio of HBeAg-positive patients
to anti-HBe–positive patients 14:10 56:40 56:40
ALT level, median U/L (range) 585 (100–2660) 157.5 (100–1940) 25 (7–50)
HBV DNA level, median copies 106/mL (range) 1.6 (!0.14–1141) 0.23 (!0.14–1261.5) 1.72 (!0.14–1313.1)
Precore region
Presence of WT only 9 (37.5) 44 (45.8) 53 (55.2)
Presence of MT 15 (62.5) 52 (54.2) 43 (44.8)
Presence of MT only 4 (16.7) 17 (17.7) 13 (13.5)
Presence of WT and MT 11 (45.8) 35 (36.5) 30 (31.3)
MT in HBeAg–positive patients, n/N (%) 9/14 (64.3)a 28/56 (50)a 17/56 (30.4)a
MT in anti-HBe–positive patients, n/N (%) 6/10 (60) 24/40 (60) 26/40 (65)
Core promoter region
Presence of WT only 12 (50) 18 (18.8) 31 (32.3)
Presence of MT 12 (50)b 78 (81.3)b,c 65 (67.7)c
Presence of MT only 6 (25) 58 (60.4) 44 (45.8)
Presence of WT and MT 6 (25) 20 (20.8) 21 (21.9)
NOTE. Data are no. (%) of patients, unless otherwise indicated. ALT, alanine aminotransferase; Anti-HBe, antibodies against hepatitis
B e antigen; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; MT, mutant; WT, wild-type.
a , by x2 test for trend.Pp .007
b .Pp .004
c .PpNS
Significance of precore and core promoter mutations. The
demographic data and the prevalence of precore and core pro-
moter mutations for the 24 patients with severe exacerbation,
96 patients with mild exacerbation, and 96 patients without
exacerbation are listed in table 3. There were no statistical dif-
ferences between the 3 groups with regard to the median age,
sex ratio, HBeAg/anti-HBe status, and HBV DNA level.
The precore and core promoter mutants, either alone or with
the wild type, were present in 62.5% and 50% of the 24 patients
with severe exacerbation, respectively. There were no significant
differences in biochemical parameters, HBV DNA levels, and
the incidence of adverse outcome in patients with or without
either the precore or the core promoter mutants. There were
also no significant differences in the prevalence of precore mu-
tants between the 3 groups of patients. However, in HBeAg-
positive patients, there was a significant trend for increasing
prevalence of precore mutants in patients without exacerbation,
with mild exacerbation, and with severe exacerbation (table 3).
This trend was not observed in anti-HBe–positive patients. The
prevalence of core promoter mutations was significantly higher
among patients with mild exacerbation than among patients
with severe exacerbation ( ), although there was noPp .004
difference when compared with patients who did not have
exacerbation.
DISCUSSION
In this study, the mortality rate for severe exacerbation of
chronic hepatitis B requiring hospitalization was 36.2%. Al-
though older age at presentation was associated with higher
mortality on univariate analysis, this factor was not shown to
be significant on multivariate analysis. There was no difference
in mortality between HBeAg-positive patients and anti-HBe–
positive patients. Therefore, HBeAg status, and probably age,
are not factors that should affect decisions regarding liver
transplantation.
However, several important indicators of poor prognosis
were identified. These included presence of cirrhosis, high
Child-Pugh score, prolonged PT, high bilirubin level, low al-
bumin level, and low platelet count at admission to the hospital.
For patients with a PT of 130 s, the mortality rate was as high
as 85.7%. For patients who also had an albumin level of 35
g/L and a bilirubin level of 1200 mM, the mortality rate in-
creased further to 92.3%.
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Serum ALT levels, both at admission and during subsequent
monitoring, did not predict mortality. In addition, the virus
load, as measured by HBV DNA levels at admission, was also
of no prognostic value. As has been described elsewhere [13],
patients frequently had undetectable or very low HBV DNA
levels by the time they presented with symptoms. To ascertain
whether the levels of HBV DNA are genuinely unrelated to the
severity of the exacerbation, a well-designed study of the HBV
DNA levels before or at the onset of exacerbation would be
required.
Our study also identified additional risk factors during sub-
sequent monitoring of the patients. These included the late in-
crease in bilirubin levels to 1290 mM, the late increase in the PT
to 133 s, and the development of ascites and encephalopathy.
Lamivudine therapy, even when provided at a relatively early
stage of exacerbation, was not linked to any survival benefit in
cases of severe HBV exacerbation. However, patients who re-
ceived lamivudine had very poor liver function at presentation.
The degree of hepatic damage was probably too severe to be
reversed by receipt of this nucleoside analogue.
We also found that the presence of precore and core pro-
moter mutations did not affect the outcome for our patients.
However, in HBeAg-positive patients, the prevalence of precore
mutations was highest in patients with severe exacerbation
(64.3%) ( ). It is quite possible that these patients ex-Pp .007
erted more-intense immunological pressure on wild-type HBV,
thus favoring the emergence of precore mutants. Among anti-
HBe–positive patients, there was no difference in the propor-
tions of precore mutants among the patients with severe or
mild exacerbation or without exacerbation. This finding is in
accord with the findings of Loriot et al. [14], who reported
that exacerbation is not related to precore mutations.
Core promoter mutants were found to occur in 81.3% of
patients with moderate exacerbation, a significantly higher
prevalence than that in patients with severe exacerbation (50%;
). In vivo studies show that the presence of core pro-Pp .004
moter mutations is associated with lower virus loads, lower
HBeAg levels, and lower DNA polymerase levels [15, 16]. It is
conceivable that the reduced production of HBeAg might give
rise to less intense immune-mediated damage.
In conclusion, several risk factors at presentation and during
subsequent monitoring have been identified as indicators of
poor prognosis for exacerbation of HBV infection. These factors
could be useful in deciding whether early liver transplantation
is warranted.
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